How much cash does Adaptive Biotechnologies generate?

Adaptive Biotechnologies (ADPT) generated -$29.1M in operating cash flow over the trailing twelve months.

What is Adaptive Biotechnologies's free cash flow?

After $2.5M of capital expenditures, Adaptive Biotechnologies's free cash flow was -$31.0M over the trailing twelve months, up 65.1% year over year.

Where does Adaptive Biotechnologies's cash flow data come from?

Every line is extracted from Adaptive Biotechnologies's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Adaptive Biotechnologies ADPT Cash Flow Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Net income	-$59.46M+62.7%	-$159.6M+29.2%	-$225.3M-12.4%	-$200.37M+6.4%
Depreciation and amortization	$16.13M-8.1%	$17.55M-14.5%	$20.53M+6.8%	$19.22M+56.9%
Stock-based compensation	$51.48M-4.0%	$53.61M-14.8%	$62.91M+13.4%	$55.48M+28.3%
Change in accounts receivable	$8.65M+131%	$3.74M—	——	$22.65M—
Change in inventories	$998K—	——	——	-$817K-115%
Change in accounts payable	——	$671K—	——	$7.11M—
Change in other assets	——	——	——	——
Other working capital changes	-$142K-426%	-$27K—	——	——
Change in deferred revenue	-$40.4M-284%	-$10.52M+64.1%	-$29.29M+48.2%	-$56.5M+2.1%
Amortization of intangible assets	$1.7M-0.2%	$1.7M+0.2%	$1.7M0.0%	$1.7M0.0%
Net cash from operating activities	-$48.04M+49.5%	-$95.21M+39.1%	-$156.32M+15.0%	-$183.95M+4.6%
Capital expenditures	$2.96M-19.2%	$3.66M-65.7%	$10.7M-34.6%	$16.35M-73.5%
Net cash from investing activities	——	$77.79M-40.0%	$129.65M—	——
Proceeds from issuance of common stock	$17.88M+7,319%	$241K-89.3%	$2.25M-71.5%	$7.89M-70.5%
Net cash from financing activities	$30.4M+12,515%	$241K-89.3%	$2.25M-98.3%	$132.27M+387%
Net increase (decrease) in cash	$22.37M—	——	-$24.43M+49.9%	-$48.78M-412%
Interest paid	$12.64M+42.6%	$8.86M-1.3%	$8.99M+1,719%	$494K—
Accretion (Amortization) of Discounts and Premiums, Investments	$2.51M-69.4%	$8.21M-10.6%	$9.18M—	——
Amortization of capitalized software and acquired intangible assets	$1.7M-0.2%	$1.7M+0.2%	$1.7M0.0%	$1.7M0.0%
Depreciation	$16.13M-8.1%	$17.55M-14.5%	$20.53M+6.8%	$19.22M+56.9%
Impairment Of Long Lived Assets	——	——	$25.43M—	——
Increase Decrease In Operating Lease Right Of Use Assets And Liabilities	-$10.45M-11.4%	-$9.39M-8.2%	-$8.68M-114%	-$4.05M—
Increase (Decrease) in Prepaid Expense and Other Assets	——	——	——	——
Inventory write-downs	——	$1.94M+39.7%	$1.39M—	——
Noncash Lease Expense	$5.36M+1.6%	$5.28M-23.7%	$6.92M-4.2%	$7.23M+2.8%
Other Noncash Income (Expense)	-$611K—	——	-$172K—	——
Revenue Interest Purchase Agreement Interest	——	-$2.62M+50.6%	-$5.3M—	——
Proceeds From Contributed Capital	——	$0—	$0—	——
Accrued payables for capital expenditures	——	——	——	——
Free cash flow	-$50.36M+49.1%	-$98.88M+40.8%	-$167.02M+16.6%	-$200.29M+21.3%
Free cash flow	-$50.36M+49.1%	-$98.88M+40.8%	-$167.02M+16.6%	-$200.29M+21.3%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Adaptive Biotechnologies.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

How much cash does Adaptive Biotechnologies generate?: Adaptive Biotechnologies (ADPT) generated -$29.1M in operating cash flow over the trailing twelve months.
What is Adaptive Biotechnologies's free cash flow?: After $2.5M of capital expenditures, Adaptive Biotechnologies's free cash flow was -$31.0M over the trailing twelve months, up 65.1% year over year.
Where does Adaptive Biotechnologies's cash flow data come from?: Every line is extracted from Adaptive Biotechnologies's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.